Total Effective Xenoestrogen Burden in Serum Samples and Risk of Endometrial Cancer in the Spanish Screenwide Case-Control Study.

"L.C. received a speaker’s honoraria from Roche. P.P.T. has received a speaker’s honoraria from Werfen. The Cancer Epidemiology Research Program (in which J.F.G., S.P., M.C.B., Y.B., P.P.T., B.P., L.A., and L.C. are affiliated) has received unrestricted grants from Merck Sharp & Dohme, and human papillomavirus test kits at no cost from Roche, supplies from Integrated DNA Technologies and Roche Diagnostics at a 50% discount, and Colli-Pee devices from Novosanis at no cost for research purposes, and a donation from GSK. The rest of authors report no conflict of interests."

"This work was conducted with the contribution of the Carlos III Health Institute through the projects PIE16/0049, PI19/01835, PI23/00790, FI20/00031, as well as through CIBERESP CB06/02/0073, ESP23PI05 and CIBERONC CB16/12/00401 and CB16/12/00234, co-financed by the European Regional Development Fund ERDF, A Way to Build Europe. This work was also supported by the Secretariat for Universities and Research of the Department of Business and Knowledge of the Generalitat de Catalunya, Roche Diagnostics, Asociación Española Contra el Cáncer Grupos estables coordinados, grants to support the activities of research groups 2021SGR01354 and 2021SGR1112, in addition to funding from the Health Department of the Generalitat de Catalunya (PERIS SLT006/17/76). We thank the Centres de Recerca de Catalunya Programme/Generalitat de Catalunya for institutional support. Some samples and data were provided by the Biobank HUB-ICO-IDIBELL, integrated into the Spanish Biobank Network and funded by the Instituto de Salud Carlos III (PT20/00171) and by the Xarxa de Bancs de Tumors de Catalunya, sponsored by Pla Director d’Oncologia de Catalunya."

"The study followed all the requirements established by the Ethics Committee for Clinical Research and was approved by the Ethics Committee for Clinical Research from the Bellvitge University Hospital (references: PR128/16 and PR348/19), as previously described in Peremiquel-Trillas et al. Participation in the study was voluntary, and all eligible participants signed an informed consent form. The Screenwide study followed the national and international directives on ethics and data protection (Declaration of Helsinki and subsequent amendments; EU Reglament 2016/679) and the Spanish laws on data protection (Organic Law 3/2018; Law 14/2007 Biomedical Research). The study was registered in the National Register of Biobanks/Collections (C.0004389)."